文献速递肿瘤 PET/CT神经核医学核素与放射性配体治疗

生长抑素类似物治疗期间[68Ga]Ga-DOTA-TOC的生物分布改变

Altered biodistribution of [68Ga]Ga-DOTA-TOC during somatostatin analogue treatment.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2024-02-26

该回顾性研究纳入35例神经内分泌肿瘤患者,比较 staging 时及第1、2周期生长抑素类似物(SSA)治疗后[68Ga]Ga-DOTA-TOC PET/CT的SUVmean与SUVmax。SSA治疗使血池活性显著升高、内脏摄取降低,该效应在第2周期后维持;间隔≤5天时血池活性显著高于更长间隔。作者建议注射兰瑞肽后5天内不做扫描。

要点

  • SSA治疗后[68Ga]Ga-DOTA-TOC PET血池活性显著升高、内脏摄取降低,第2周期后仍维持。
  • 血池示踪剂可用性与内脏结合呈负相关,与原发性肿瘤摄取呈正相关。
  • 间隔≤5天时血池活性显著高于更长间隔,作者建议注射兰瑞肽后5天内不做扫描。

核心结论

  • SSA治疗后[68Ga]Ga-DOTA-TOC生物分布改变,绝对SUV比较应谨慎并考虑该改变。
  • 作者建议注射兰瑞肽后最初5天内不进行扫描。

研究设计与样本

  • 回顾性纳入35例神经内分泌肿瘤(NENs)患者。
  • 纳入分期时及第1、2周期SSA治疗后的[68Ga]Ga-DOTA-TOC PET,测定血、内脏器官、原发肿瘤和两个转移灶的SUVmean与SUVmax。
  • 记录SSA治疗与PET扫描之间的间隔。

主要发现

  • SSA治疗导致血池活性显著升高、内脏示踪剂摄取降低,第2周期SSA治疗后该效应维持。
  • 血池示踪剂可用性与内脏示踪剂结合呈负相关,与原发性肿瘤示踪剂摄取呈正相关。
  • 间隔≤5天时血池活性显著高于更长间隔。

临床怎么用

  • 作者建议注射兰瑞肽后最初5天内不进行[68Ga]Ga-DOTA-TOC PET扫描。
  • 作者认为[68Ga]Ga-DOTA-TOC PET的绝对SUV比较应谨慎,需考虑SSA治疗后的示踪剂生物分布改变。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The need for an interval between the administration of long-acting Somatostatin Receptor Analogues (SSA) and the [68Ga]Ga-DOTA-TATE PET has been questioned based on recent literature in the new EANM guidelines. Here an earlier studies showed that SSA injection immediately before SSTR PET had minimal effect on normal organ and tumor uptake (1). However, data are scarce and there are (small) differences between [68Ga]Ga-DOTA-TATE and [68Ga]Ga-DOTA-TOC binding affinity, and it remains unknown whether these findings can be directly translated to scans with [68Ga]Ga-DOTA-TOC as well. The purpose of this study was to assess the effect of SSA use on the biodistribution in a subsequent [68Ga]Ga-DOTA-TOC PET/CT and compare this intra-individually across several cycles of SSA treatments. METHODS: Retrospectively, 35 patients with NENs were included. [68Ga]Ga-DOTA-TOC PET at staging and after the 1st and 2nd cycle of SSA were included. SUVmean and SUVmax of blood, visceral organs, primary tumor and two metastases were determined. Also, the interval between SSA therapy and the PET scan was registered. RESULTS: Treatment with SSA resulted in a significantly higher bloodpool activity and lower visceral tracer uptake. This effect was maintained after a 2nd cycle of SSA therapy. Furthermore, there was an inverse relationship between bloodpool tracer availability and visceral tracer binding and a positive correlation between bloodpool tracer availability and primary tumor tracer uptake. With an interval of up to 5 days, there was a significantly higher bloodpool activity than at longer intervals. CONCLUSION: Absolute comparison of the SUV on [68Ga]Ga-DOTA-TOC PET should be done with caution as the altered biodistribution of the tracer after SSA treatment should be taken into account. We recommend not to perform a scan within the first 5 days after the injection of lanreotide.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. van de Weijer T, Bemer F, de Vos-Geelen J, et al. Altered biodistribution of [68Ga]Ga-DOTA-TOC during somatostatin analogue treatment. Eur J Nucl Med Mol Imaging. 2024. PMID: 38403723. doi:10.1007/s00259-024-06659-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。